ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: Thyroid effects of tyrosine kinase inhibitors
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: Thyroid effects of tyrosine kinase inhibitors
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF ENDOCRINOLOGY
Volume 171, Issue 3, Pages R91-R99
Publisher
Bioscientifica
Online
2014-05-16
DOI
10.1530/eje-14-0198
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Thyroid Hormone Inactivation in Gastrointestinal Stromal Tumors
- (2014) Michelle A. Maynard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Authentic Bosutinib Inhibits Triiodothyronine Transport by Monocarboxylate Transporter 8
- (2014) Doreen Braun et al. THYROID
- Case of Sorafenib-Induced Thyroid Storm
- (2013) Sigurdis Haraldsdottir et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Thyroid Dysfunction in Patients Treated With Sunitinib or Sorafenib
- (2012) Julia Clemons et al. Clinical Genitourinary Cancer
- Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: A cohort study
- (2012) Sandra Feldt et al. EUROPEAN JOURNAL OF CANCER
- Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial
- (2012) T C Schneider et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Sorafenib therapy decreases the clearance of thyrotropin
- (2012) Herman Verloop et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer
- (2012) Egidio Del Fabbro et al. JOURNAL OF CHEMOTHERAPY
- Severe hypothyroidism presenting as myxedema coma in the postoperative period in a patient taking sunitinib: case report and review of literature
- (2012) Abhijit V. Lele et al. JOURNAL OF CLINICAL ANESTHESIA
- Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma
- (2012) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
- (2012) David C. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Inappropriate Elevation of Serum Thyrotropin Levels in Patients Treated with Axitinib
- (2012) Kenji Ohba et al. THYROID
- Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?
- (2011) R. Sabatier et al. ANNALS OF ONCOLOGY
- Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population
- (2011) Merina Ahmed et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia
- (2011) Tetsuichi Yoshizato et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Endocrine Effects of the Tyrosine Kinase Inhibitor Vandetanib in Patients Treated for Thyroid Cancer
- (2011) Maryse Brassard et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Sunitinib-Induced Hypothyroidism Is due to Induction of Type 3 Deiodinase Activity and Thyroidal Capillary Regression
- (2011) Mariëtte H. W. Kappers et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Tyrosine Kinase Inhibitors Noncompetitively Inhibit MCT8-Mediated Iodothyronine Transport
- (2011) Doreen Braun et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Richard H. de Boer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2011) Ronald B. Natale et al. JOURNAL OF CLINICAL ONCOLOGY
- Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
- (2011) Hagop M Kantarjian et al. LANCET ONCOLOGY
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sorafenib Induced Thyroiditis in Two Patients with Hepatocellular Carcinoma
- (2011) Leni van Doorn et al. THYROID
- Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
- (2010) Bruce G. Robinson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Sorafenib-Induced Hypothyroidism Is Associated with Increased Type 3 Deiodination
- (2010) Randa M. Abdulrahman et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
- (2010) Roy S Herbst et al. LANCET ONCOLOGY
- Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
- (2010) Keith C Bible et al. LANCET ONCOLOGY
- The tricyclic antidepressant desipramine inhibits T3 import into primary neurons
- (2010) Stephan Roth et al. NEUROSCIENCE LETTERS
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Shrinkage of Thyroid Volume in Sunitinib-Treated Patients with Renal-Cell Carcinoma: A Potential Marker of Irreversible Thyroid Dysfunction?
- (2010) Aljosja Rogiers et al. THYROID
- Sunitinib Induces Hypothyroidism with a Markedly Reduced Vascularity
- (2010) Noriko Makita et al. THYROID
- Sorafenib-Induced Destructive Thyroiditis
- (2010) Massimo Iavarone et al. THYROID
- Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
- (2010) Theo D. Kim et al. THYROID
- Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib
- (2010) L. M. Riesenbeck et al. WORLD JOURNAL OF UROLOGY
- Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma
- (2009) Hendrieke Hoftijzer et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer
- (2009) Martin J. Schlumberger et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
- (2009) Richard T. Kloos et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation
- (2008) P Wolter et al. BRITISH JOURNAL OF CANCER
- Thyrotoxicosis during sunitinib treatment for renal cell carcinoma
- (2008) Mathis Grossmann et al. CLINICAL ENDOCRINOLOGY
- Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients
- (2008) José Miguel Dora et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Phase II Trial of Sorafenib in Advanced Thyroid Cancer
- (2008) Vandana Gupta-Abramson et al. JOURNAL OF CLINICAL ONCOLOGY
- Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
- (2008) Steven I. Sherman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncogenes and Cancer
- (2008) Carlo M. Croce NEW ENGLAND JOURNAL OF MEDICINE
- Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib
- (2007) I. Tamaskar et al. ANNALS OF ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started